ArriVent BioPharma(AVBP) - 2025 Q2 - Quarterly Results

Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2025 Financial Results NEWTOWN SQUARE, PA, August 11, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent Company progress. "Firmonertinib continues to advance with strong momentum toward registration, ...